IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ:IDYA) announced the acceptance of an abstract for oral presentation at the 2025 Society for Melanoma Research Congress in Amsterdam. The presentation will feature the first-ever median overall survival data from their Phase 1/2 trial evaluating the combination of darovasertib and crizotinib in first-line metastatic uveal melanoma (mUM).

The study, known as OptimUM-01, includes data from over 40 patients. Dr. Meredith McKean from Sarah Cannon Research Institute will present the findings at the congress, which takes place from October 25-28, 2025. The detailed data from the abstract will be disclosed at a future date.

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's single-arm, Phase 1/2 trial of darovasertib in combination with crizotinib in first-line metastatic uveal melanoma (mUM) was accepted for an oral presentation at the 2025 Society for Melanoma Research Congress (SMR), taking place on October 25-28 in Amsterdam. The presentation will include data from over 40 patients in the trial, including the first reported median overall survival (OS) data for the combination of darovasertib and crizotinib in mUM. A detailed summary of the data from the abstract will be shared at a later date. 

Details of the Presentation are as follows:

Title (Abstract #209): First reported overall survival results from a phase 1/2 study of darovasertib (OptimUM-01) plus crizotinib as first-line treatment for metastatic uveal melanoma

Presenter: Dr. Meredith McKean, MD, MPH; Director, Melanoma and Skin Cancer Research at Sarah Cannon Research Institute

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of IDEAYA therapeutics, including combination therapies; and (ii) the timing and content of an oral/poster presentation at the 2025 SMRC related to data from a Ph 1/2 trial of darovasertib in combination with crizotinib in 1L mUM. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' in early or late stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer  
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-first-median-overall-survival-data-from-phase-2-trial-of-the-darovasertib--crizotinib-combination-in-metastatic-uveal-melanoma-at-the-2025-society-for-melanoma-research-congress-302542236.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What will IDEAYA Biosciences (IDYA) present at the 2025 SMR Congress?

IDEAYA will present the first median overall survival data from their Phase 1/2 trial of darovasertib and crizotinib combination in metastatic uveal melanoma.

How many patients were included in IDEAYA's (IDYA) Phase 1/2 trial of darovasertib?

The trial included data from over 40 patients treated with the combination of darovasertib and crizotinib in first-line metastatic uveal melanoma.

When and where will IDEAYA (IDYA) present their melanoma trial results?

The results will be presented at the 2025 Society for Melanoma Research Congress taking place October 25-28 in Amsterdam.

Who will present IDEAYA's (IDYA) clinical trial data at the 2025 SMR Congress?

Dr. Meredith McKean, Director of Melanoma and Skin Cancer Research at Sarah Cannon Research Institute, will present the data.